|Bid||5.20 x 1100|
|Ask||5.90 x 1000|
|Day's Range||5.26 - 5.41|
|52 Week Range||2.08 - 6.82|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2019 - Mar 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.67|
NEW YORK, March 12, 2019 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.
NEW YORK, Feb. 11, 2019 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a Fortress Biotech (NASDAQ: FBIO) company, today announced the completion of the first stage.
Avenue Therapeutics (ATXI) will hold its special meeting of shareholders on February 6, 2019 to consider the stock purchase and merger agreement proposed by InvaGen Pharmaceuticals. On November 13, 2018, Avenue announced an acquisition with InvaGen Pharmaceuticals which will initially provide $35 million in capital for a one-third stake in the company. Following FDA approval and the desired label, InvaGen will complete its acquisition of the company for an estimated $13.92 per share plus contingent rights to payments related to revenue and profit levels.
Stull, Stull & Brody (“SS&B”) announces that a class action lawsuit has been filed and it is investigating the Board of Directors of Avenue Therapeutics, Inc. ("Avenue" or the "Company") (ATXI) for possible breaches of fiduciary duty related to the sale of the company to InvaGen Pharmaceuticals, Inc. and Madison Pharmaceuticals, Inc. Under the terms of the proposed transaction, Avenue shareholders are only anticipated to receive $13.92 for each share of Avenue common stock owned.
NEW YORK , Dec. 12, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
By John Vandermosten, CFA NASDAQ:ATXI READ THE FULL ATXI RESEARCH REPORT Avenue Therapeutics (NASDAQ:ATXI) released third quarter 2018 financial results and submitted their Form 10-Q to the SEC on November ...
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NEW YORK, Nov. 14, 2018 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of.
Avenue Therapeutics (ATXI) announced an acquisition agreement with InvaGen Pharmaceuticals to acquire a 33.3% stake in the company for $35 million to be followed by a second stage closing in 2021 which will acquire the remaining shares for up to $180 million, subject to FDA approval and other specific terms. 5.8 million new shares will be issued at $6 per share, providing sufficient capital to advance IV tramadol to the post-approval stage. Furthermore, if the FDA grants approval and certain milestones are met, shareholders will receive payment of an estimated $13.92 per share and be eligible for contingent post-transaction consideration based on sales and profit metrics.
MUMBAI, India & NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- InvaGen Pharmaceuticals Inc. (“InvaGen”), a subsidiary of the leading global pharmaceutical company Cipla Limited, today announced that it has entered into definitive agreements with two closing stages for a proposed acquisition of Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a Fortress Biotech (FBIO) company focused on the development and commercialization of intravenous (IV) Tramadol. The transaction will be subject to Avenue stockholders’ and regulatory approvals, and other closing conditions.
By John Vandermosten, CFA NASDAQ:ATXI READ THE FULL ATXI RESEARCH REPORT Avenue Therapeutics (NASDAQ:ATXI) provided their press release and their form 10-K including second quarter 2018 financial results ...
Last August, National Securities Corp analyst Jonathan Aschoff was bullish on Avenue Therapeutics Inc (ATXI.O), a fledgling biotechnology company with no revenue and one drug in clinical trials. Nearly a year later, Avenue shares are down 36 percent, at about $4. A few months earlier, Aschoff had waxed equally optimistic about another biotech venture, Checkpoint Therapeutics Inc (CKPT.O), with several cancer drugs in various stages of development.
Avenue Therapeutics (ATXI) hosted a moderated discussion on tramadol on June 11 which featured two key opinion leaders (KOLs) in the space. The participants were Dr. Neil Singla and Dr. Harold Minkowitz. Dr. Singla brings a long history developing analgesic medicines to the discussion.
LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Avenue Therapeutics, Inc. (NASDAQ: ATXI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ATXI as the Company's latest news hit the wire. On May 21, 2018, the Company announced that its first pivotal Phase-3 trial assessing IV tramadol for treatment of patients with moderate to moderately severe postoperative pain following bunionectomy surgery achieved the primary endpoint of a statistically significant improvement in Sum of Pain Intensity Difference over 48 hours (SPID48) compared to placebo. Active-Investors.com is currently working on the research report for Taro Pharmaceutical Industries Ltd (NYSE: TARO), which also belongs to the Healthcare sector as the Company Avenue Therapeutics.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Fibrocell Science Inc (NASDAQ: FCSC ) stock gained ...
By John Vandermosten, CFA NASDAQ:ATXI Avenue Therapeutics (NASDAQ:ATXI) circulated a press release and their form 10-K with their first quarter 2018 financial results on May 3rd. Total expenses for the ...
Avenue Therapeutics (ATXI) is developing IV tramadol for postoperative pain. Avenue has licensed a patented administration of IV tramadol that is able to limit side effects and provide a solution for moderate to severe pain which avoids many of the risks of opioids and non-steroidal anti-inflammatory drugs (NSAIDs). The drug also allows for transition to step down therapy with oral tramadol, which mirrors the pharmacokinetic, side effect profile and pain control of the IV form.